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MOLECULAR-GENETIC STUDIES FOR HCV INFECTION
Tajiev B.M., Rashidov F.A., Alimov M.M.
Tashkent Pediatric Medical Institute
Abstract
Background. HCV infection is a dangerous disease that can lead to cirrhosis and
hepatocellular carcinoma. There are several genotypes and many subtypes of the virus. Yet,
the prevalence of each type and subtype is largely varies throughout the world. Furthermore,
the sensitivity for the treatment and aggressiveness of one type of the virus widely differs
compared to another one.
Methods. 120 patients were examined with chronic viral hepatitis C hospitalized from
2002 to 2009 at the clinic of the Research Institute of Virology and at the 5th City Clinical
Infectious Disease Hospital. All participants of the study experienced a comprehensive
clinical and laboratory examination during the dynamic observation.
Results.The obtained research results showed that 1b and 1a genotypes cause a more
pronounced necrotic inflammatory process in hepatocytes. This fact proves the more
aggressive antigenic and pathogenic properties of the 1b and 1a genotypes in comparison
with the 2a, 3a and 1b + 3a genotypes of HCV.
Conclusion. Specific characteristics of the HCV were observed in the patients with
different genotypes, which was reflected in clinical and laboratory changes in HCV infection.
Keywords. Clinical and laboratory features, viral hepatitis C, genotypes of viral hepatitis
C.
BACKGROUND
Among the most important problems of
practical health care and scientific medicine,
viral hepatitis is one of the leading health
issues nowadays. According to data
presented by WHO, about 50 million people
in the world infected with viral hepatitis
annually, and up to 2 million people die.
Recently, physicians all-around the world
have been attracted by viral hepatitis C
(HCV) (Nematova&Fayziboev, 2016; and
Sokolova, 2003). Latent course with
frequent transition to a chronic form and
subsequent development of severe
complications creates a serious problem for
on time diagnosis and treatment of such
patients (Ignatova&Serov, 2001; and Orlova
et al, 2002).
Chronic HCV infection can lead to liver
fibrosis, cirrhosis, and hepatocellular
carcinoma. HCV is classified into 7
genotypes and 67 subtypes (Smith et al.,
2014). In North America, the majority of
HCV infections are caused by genotype 1, 2,
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and 3 (Zein et al., 1996). Although not well
known for the scientific society, highly
effective, direct acting antivirals against
HCV are available today.
In addition to serious consequences for
the patients, in the absence of treatment,
they become a source of infection for others.
Significant morphological rearrangement of
the liver in chronic hepatitis C, up to
fibrosis, occurs even with a latent course of
the process, which is only clinically
manifested in the terminal stage
(Abdukadyrova, 2002; Pokrovsky et al,
2003; and Mirtazaev et al, 2003). Currently,
many aspects of the studies and treatment of
HCV remain unresolved. The dependence of
clinical manifestations on the genotype of
the virus has not been fully studied yet. A
deeper study and comparison of clinical,
virological and morphological changes in
HCV at the present stage is required
depending on the molecular genetic variants
of HCV.
HCV can be genotyped using various
methods including the gold standard -
sequencing, real-time reverse transcriptase -
PCR, and reverse hybridization line probe
assays (LiPA) (Verbeeck et al., 2008, Larrat
et al., 2013) (cited in Olmstead et al, 2017).
A real-time RT-PCR, being a laboratory
based test for identification the genomes,
genotyping assay was explored as an
approach for low-cost, high-throughput
screening of major HCV genotypes and
subtypes. Various primer/probe
combinations targeting the HCV Core, E1,
and NS5B genomic regions were tested. A
paired, duplex real-time RT-PCR assay that
targets HCV Gt 1a and 3a in one reaction
and Gt 1b and 2 in another reaction was
ultimately validated using samples
genotyped by LiPA (Olmstead et al, 2017).
PURPOSE OF THE STUDY
To conduct molecular-genetic studies in
HCV infection in order to elucidate the
genetic type of the virus in different forms
of HCV infection.
MATERIAL AND METHODS
STUDY POPULATION
We examined 120 patients with chronic
viral hepatitis C hospitalized from 2002 to
2009 at the clinic of the Research Institute
of Virology and at the 5thCity Clinical
Infectious Disease Hospital. All patients
underwent a comprehensive clinical and
laboratory examination during the dynamic
observation.
INCLUSION AND EXCLUSION
CRITERIA
The diagnosis of the disease was
verified by detection of RNA of the HCV by
PCR. Furthermore, the virus was genotyped.
Patients with markers of other viral hepatitis
were excluded from the analysis.
All examined patients were classified
according to the international classification
of chronic hepatitis, adopted in 1994 in Los
Angeles. Patients with LC were diagnosed
according to the Child-Pugh predictive
scale, improved by A.I. Khazanov and N.N.
Nekrasova and were included in classes A,
B and C.
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RESULTS
All patients were found to have anti-
HCV. Among the examined patients, 61
(50.8%) were female, and 59 (49.2%) were
men. The main age of patients was 41.4 ±
1.3 years (ranged from 17 to 70). In the age
aspect, 3 (2.5%) patients aged from 14 to 20
years old, 19 (15.8%) aged from 21 to 30
years old patients, from 31 to 45 years old
(41.7%) patients, from 46 to 60 years of age,
37 (30.8%) and over 60 years old -11 (9.2%)
patients (Table 1).
Table 1.
Distribution of patients by gender and age
Age, years Women Men Total
Abs % Abs % Abs %
14-20 - - 3 2,5 3 2,5
21-30 7 5,8 12 10,0 19 15,8
31-45 29 24,2 21 17,5 50 41,7
46-60 18 15.0 19 15,8 37 30,8
60 and more 7 5,8 4 3,4 11 9,2
Total 61 50,8 59 49.2 120 100
The results of an epidemiological
history showed that 34 (28.3 ± 4.1) patients
noted a previous acute form of the
disease.During the observations of 120
patients with chronic viral diseases of the
liver, the developed liver cirrhosis (LC) was
diagnosed in 20 (16.7%). Among the
remaining 100 (83.3%) patients, chronic
viral hepatitis C (CVHC) of varying degrees
of activity of the pathological process was
determined. In most cases, the disease
progressed in latent form in 67 (55.8%)
patients, in 28 (23.3%) in a sluggish form,
and in 25 (20.9%) patients the disease
proceeded in an active form. Chronic
hepatitis of minimal activity (CHMinA) was
diagnosed in 18 (15.0%) patients, chronic
hepatitis of moderate activity (CHModA) -
in 52 (43.3%) patients, average chronic
hepatitis (CHAA) - in 22 (18.3%) patients
and 28 (23.4%) have high activity chronic
hepatitis (CHHA).
As a result of the studies revealed the
circulation of 3 genotypes of HCV.
Molecular genetic variants of circulating
viruses were distributed as follows; among
the patients, 1b HCV-y genotype was
diagnosed in 67 (55.8%) patients, 1a in 8
(6.7%), 2a in 15 (12.5%), 2c in 2 (1.7%), 3a
20 (16.7%) and mixed genotype 1b + 3a in 8
(6.7%) patients (Figure 1). Subsequently,
clinical, laboratory, instrumental and
pathomorphological studies were carried out
depending on the HCV genotype. In patients
with the genotype 1b in 10.5% of cases, the
clinical course was defined as CHMinA,
CHModA was observed in 44.8% of
patients, CHAA in 13.4% and in 31.4% of
patients. LC among patients with the 1b
genotype was diagnosed in 20.9% of cases.
Among patients with the genotype 1a,
12.5% were diagnosed with CHMinA, in
37.5% of cases of CHModA. CHAA in
25.0% and in 25.0% of CHHA.LC
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formation was detected in 25.0% of patients.
An analysis of the activity of the process in
patients with genotype 2a revealed CHMinA
in 26.7% of patients, in 46.6% of CHAA, in
20.0% of CHModA and in 6.7% of CHHA.
LC was formed in 13.3% of patients.
Fig. 1. Molecular-genetic variations of
HCV
Among patients with the 2b genotype,
50% were determined as CHModA and in
50% as CHAA, CHMinA and CHHA and
the formation of LC in patients of this group
was not recorded. Among patients with the
3a genotype, CHMinA was observed in
20.0% of cases, in 40.0% of CHAA, in
25.0% of patients with CHModA, in 15.0%
of CHHA. LC formation was noted in
10.0% of patients. With a mixed genotype
1b + 3a-in most cases, 37.5% was
determined by CHAA, in 25.0% of
CHModA, in 25.0 patients with CHAA and
in 12.5% of patients with CHHA. It should
be noted that the formation of LC is
diagnosed among patients with 1b, 1a, 2a,
for HCV genotypes. Symptoms
characteristic of LC were not observed in
patients with mixed 1b + 3a genotype and
2b HCV genotype. An analysis of clinical
manifestations showed that 50 (74.6%)
patients of the first group with the 1b
genotype more often complained of
asthenovegetative syndrome, which was
manifested by weakness and rapid fatigue.
Patients with genotype 1a and patients with
genotype 3a of HCV complained of similar
complaints in 5 (62.5%) cases in 9 (45.0%)
cases. Patients in whom the mixed 1b + 3a
genotype was detected in 5 (62.5%) cases
also complained of weakness and fatigue. In
6 (40.0%) cases, patients with genotype 2a
complained of asthenovegetative symptoms.
For liver enlargement, which was
accompanied by pain in the right
hypochondrium, 38 (56.7%) patients with
genotype 1b were treated. Patients with
genotype 1a pain in the right
hypochondrium were noted in 4 (50.0%)
cases, patients with genotype 3a were noted
in 9 (45.0%) patients in 3 (37.5%) patients
with mixed HCV genotype 1b + 3a and 7
(46.7%) patients with genotype 2a also
noted an unpleasant sensation and pain in
the right hypochondrium. Jaundice in the
form of ictericity of the skin and mucous
membranes of different intensities was
observed in 11 (16.4%) patients. 1b
genotype, 1 (12.5%) with 1a genotype, 5
(25.0%) with 3a genotype, 1 (12.5%) with
1b + 3b genotype and 2 (13.3%) with 2a
with the HCV genotype. In observations, a
symptom of cholestasis in the form of skin
itching was observed in 8 (11.9%) patients
with genotype 1b, 2 (25.0%) with genotype
1a, 3 (15.0%) with genotype 3a, and 1
(12.5%) 1b + 3a genotype. In the observed
patients with genotype 2a, in 1 (6.7%)
patient.
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Symptoms like mucosal bleeding were
detected in 15 (22.4%) patients, and 12
(17.9%) patients with genotype 1b also
complained of sleep inversion. In patients
with the genotype 1a, hemorrhagic
disturbances were revealed in 2 (25.0%)
patients and in 1 (12.5%) sleep inversion.
The same disorders were detected in 3
(15.0%) patients and in 2 (10.0%) patients
with the 3rd type of HCV genotype. In
patients with mixed 1b + 3a genotype,
bleeding from the mucous membranes was
noted in 12.5% of cases, and sleep inversion
was noted in 2 (25.0%) patients. 2 (13.3%)
patients complained of hemorrhagic
disorders, and 1 (6.7%) patients with HCV
genotype 2a complained of sleep inversion.
14 (20.9%) patients with 1b genotype, 2
(25.0%) patients with 1a genotype, 2 (10%)
patients with 3a genotype, 2 (13.3%)
patients with 2a genotype complained of
weight loss. Patients infected with 1b + 3a
of the virus genotype did not complain of
this nature. 6 (9.0%) patients with 1b
genotype complained of abdominal
enlargement, 2 (25%) with 1a genotype, 1
(5%) with 3a genotype and 1 (6.7%) patient
with a 2a genotype. One of the main
symptoms of chronic liver damage is
hepatomegaly. 40 (59.7%) patients with a
genotype 1b complained of an increase in
liver size, 5 (62.5%) patients with a
genotype 1a, 8 (40.0%) patients with a
genotype 3a, and 3 (37.5%) patients with 1b
+ 3a genotype and 6 (40.0%) patients with
2a HCV genotype. Palmar erythema was
observed in 38 (56.7%) patients with
genotype 1b, in 4 (50.0%) patients with
genotype 1a, in 8 (40.0%) with genotype 3a,
in 5 (33.3%) patients with 2a genotype and
in 2 (25%) patients with 1b + 3 and the
HCV genotype. Teleangiectasias and spider
veins on the chest and anterior abdominal
wall were detected in 14 (20.9%) patients
with the 1b genotype, in 2 (25.0%) patients
with the 1st genotype, in 2 (20.0%) with the
3rd genotype, in 2 (13.3%) patients with a
2a gene type. Splenomegaly was determined
in 13 (19.4%) patients with the 1st genotype,
in 2 (25.0%) patients with the 1st genotype,
in 2 (10.0%) patients with the 3rd genotype
and in 1 (6.7%) 2a with the HCV genotype.
It should be noted that in patients of these
groups in 12 cases (60.0%), class B and C
LCs were diagnosed, and in the remaining 8
(40.0%), class A was revealed according to
the Child-Pugh classification - in patients
with 1b genotype in 10 (14.9%) cases, vein
expansion of the lower third of the
esophagus was observed. The same changes
were observed with 1a genotype in 12.5% of
patients with 3a genotype in 5.0% of cases
and in patients with 2a genotype in 6.7% of
cases. The formation of ascites was
observed with 1b genotype in 8 (11.9%)
patients, with 1a genotype in 2 (25%)
patients, with 3a genotype in 1 (5.0%) cases
and with 2a genotype in 1 (6.7 %) of the
patient.
Extrahepatic manifestations in the form
of autoimmune thyroiditis were observed in
13 (19.4%) patients with 1b genotype, in 1
(12.5%) patient with 1a genotype, in 2
(10.0%) patients with 3a genotype, in
patients with mixed genotype 1b + 3, and
autoimmune thyroiditis was observed in 2
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(25%) cases and in 3 (20%) patients with the
2a virus genotype. Symptoms of arthritis
were diagnosed in 14 (20.9%) patients with
1b genotype, in 2 (25%) patients with 1a
genotype, in patients with 3a genotype - in 4
(20.0%) cases, with 1b + 3a - in 1 (12.5%)
patient and in 1 (6.7%) patient with
genotype 2a. Renal disorders in the form of
glomerulonephritis were diagnosed in 5
(7.5%) patients with 1b genotype and in 1
(6.7%) patient with 1b + 3a HCV genotype.
The ALAT index as an indicator of
cytolysis was: for genotype 3a, 2.8 ± 0.4
μmol/l, for genotype 1a, the indices were 1.5
± 0.6 μmol/l, 3.2 ± 0.5 μmol/l was
determined at 1b + 3a genotype, with 1b and
2a genotype, 1.6 ± 0.7 μmol/l and 1.3 ± 0.4
μmol/l, respectively. Indicators of ALAT at
3a and mixed 1b + 3a genotype significantly
differed from the indicators of other groups
(P <0.05) (table 2)
.
Table 2
Laboratory parameters of different genotypes of HCV
Indexes 1b 1а 2а 3а 1b+ 3а
ALAT μmol/l 1,6±0,7 1,5±0,6 1,5±0,4 2,8±0,4* 3,2±0,5*
Thymoltest
Units
33,6±12,6 22,6±4,6 14,4±3,7 7,0±2,0 19,6±6,7
Alkalinephosphatase
Units/l
298±56,6 188±17,8 263±19,7 254,5±25,5 282±65,2
PTI
%
77,3±3.4 75,4±2,7 74,3±1,9 71,0±2.5 77,3±6,9
* The difference is significant in comparison with other groups.
Thymol test averaged 33.3±12.6;
22.6±4.6, 19.6±6.7; 14.4±3.7 and 7.0±2.0
units in 1b, 1a, 1b + 3a, 2a and at 3a
genotype, respectively, and during dynamic
observation tended to decrease. The activity
of alkaline phosphatase increased
significantly, the average indicators were
298 ± 56.6, 188 ± 17D 282.0 ± 65.2, 263 ±
19.7, and 254.5 ± 25.5 mmol/l at 1b. 1a, 1b
+ 3a, 2a and with 3a genotype, respectively.
The average level of the prothrombin index
was 77.3 ± 3.4%, 75.4 ± 2.7%, 77.3 ± 6.9%,
74.3 ± 1.9%, and 71.0 ± 2.5% with 1b, 1a,
1b + 3a, 2a and with the genotype,
respectively.
DISCUSSIONS
Thus, the results of clinical studies have
shown that the 1b and 1a genotypes cause a
more pronounced pathological process,
which indicates a more aggressive antigenic
and pathogenic properties of these
genotypes compared with 2a, 3a and 1b + 3a
of the HCV genotypes. With mixed 1b + 3a
genotypes, indicators of the degree of
activity of the pathological process could be
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compared with those of infected patients
with the 1b genotype, which in turn
indicates the leading role of the 1b genotype
in HCV infection with mixed genotypes.
The indicators of the necrotic inflammatory
process in the liver with genotype 3a were
not pronounced, which testified to the non-
aggressive antigenic and pathogenic
properties of this genotype. In our opinion,
the minimal activity of the pathological
process in the liver with the HCV genotype
2a is associated with less pronounced
cytopathic and antigenic properties of this
genotype in comparison with the above
HCV genotypes.
In one very interesting research
conducted in several provinces of China, in
total, 4 HCV genotypes and 18 subtypes
were identified among more than 32 000
patients. From them, 5 dominant subtypes
were detected from 99% of the
samples.Genotypes 4, 5 and 7 were not
detected. No mixed infections with rare
subtypes were found. Males, compared with
females, showed higher HCV subtype
diversity, a lower percentage of HCV1b and
2a and a higher percentage of rare subtypes
and mixed infections. The analyses revealed
the comprehensive distribution patterns of
HCV genotypes in the general population of
mainland China. HCV genotypic patterns
were differentially distributed on the basis
of geography, sex and age (Chen et al,
2017).
In the United States, on the other hand,
HCV genotypes 1a and 1b are the most
commonly found genotypes in patients with
chronic HCV. Infection with
HCV genotype 1b can be associated with
more severe liver disease and may have a
higher risk for the development of liver
cancer including hepatocellular carcinoma.
HCV genotype 2b is more likely to be the
most sensitive and HCV genotype 1b was
the least sensitive to interferon therapy
(Zein&Persing, 1996).
According the results of research by
Tsukiyama-Kohara et al. (2017),
HCV genotypes distribution varies based on
geography. Moreover,
each genotype associate with different
tolerance to interferon treatment. Recently-
developed direct-acting antiviral (DAA)
drugs, which target viral proteases or
polymerases, mediate drastically better
antiviral effects than previous therapeutics.
Although treatment with DAAs has led to
the development of drug-resistant HCV
mutants, the most recently approved DAAs
show improved pan-genomic activity, with a
higher barrier to viral resistance.
CONCLUSION
Summarizing, it can be argued that
specific characteristics of the virus were
observed in patients with different
genotypes, which was reflected in clinical
and laboratory changes in HCV infection.
STUDY LIMITATIONS
The study was conducted on the patients
with no information of their living area of
our Republic, so we could not reveal the
prevalence of different genotypes of the
virus in different area of Uzbekistan. To
uncover long-term outcomes of the HCV
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infection and the results of treatment, more
studies should be carried out on this topic.
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